Introduction:
Last Updated 1 September 2010Parkinson’s disease (PD) is one of the most common chronic
neurodegenerative diseases in the elderly. The PD therapy market features a
high rate of polypharmacy that is unique among neurological disorders, driven
by the need to manage primary motor symptoms and nonmotor symptoms of the
disease as well as the need to manage complications associated with levodopa
(multiple brand, generics), the drug that remains at the core of PD treatment.
High drug-treatment rates, the high rate of polypharmacy and several key areas
of unmet need combine to make the PD market one of high-growth opportunity.
Questions Answered in This Report:
*
Once-daily formulations of dopamine agonists are competing in a
market traditionally dominated by immediate-release (IR) formulations.
How
have the new formulations affected the use of traditional dopamine agonists?
How will novel once-daily formulations of dopamine agonists fare in the face of
generics competition from IR formulations? How does this dynamic differ among
the major markets under study (United States, France, Germany, Italy, Spain,
United Kingdom, Japan)? Which dopamine agonist will become the market leader?
*
Leading PD drugs will face generics competition during the
2009-2019 forecast period.
How will genericization affect the overall
market? How will the presence of generics impact the uptake of novel emerging
agents?
*
The results of the ADAGIO study, which suggest a
disease-modifying effect for the monoamine oxidase (MAO)-B inhibitor rasagiline
(Teva Pharmaceuticals/Lundbeck Azilect/Agilect), will affect treatment
algorithms in early PD.
What is the opinion of interviewed experts regarding
the ADAGIO trial results? How will uptake of rasagiline change over the
forecast period?
*
Kyowa Hakko Kirin/Biovail Pharmaceuticals’ adenosine A2A
antagonist istradefylline has re-entered clinical development for PD in the
United States; development was discontinued after the FDA issued a
not-approvable letter in February 2008. Development of another A2A adenosine
antagonist, Biogen Idec/Vernalis’s vipadenant, was discontinued in July 2010
because of negative toxicological findings in preclinical studies.
What are
thought leaders opinions’ of the potential of adenosine A2A receptor
antagonists as novel treatments for PD? Where in the PD treatment algorithm do
interviewed experts expect an agent from this drug class to fall? Which
adenosine A2A receptor antagonist currently in development holds the most
potential? What other novel nondopaminergic therapies in development have
potential in the PD market?Scope:
Markets covered: United States, France, Germany, Italy,
Spain, United Kingdom, Japan.
Primary research: 40 country-specific interviews with
movement disorder specialists and neurologists.
Epidemiology: Prevalence of PD by country and age-group
(< 65 years and ≥ 65 years). Percentage of PD patients affected by
dementia.
Emerging therapies: Phase II: 18 drugs; Phase III/PR: 7
drugs; coverage of 28 select preclinical and Phase I products.
Market forecast features: Using market research, primary
research with key opinion leaders, and our proprietary forecasting model, we
forecast population sizes and sales of PD therapies through 2019.
Alternative market scenarios: U.S. launch of Kyowa Hakko
Kirin/Biovail’s adenosine A2A antagonist istradefylline. U.S. and European launches
of Acadia Pharmaceuticals/Biovail’s pimavanserin for PD psychosis and Santhera
Pharmaceuticals/Biovail’s alpha 2A adrenergic receptor antagonist fipamezole as
levodopa-adjunctive therapy for advanced PD.